CS32582 is a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2 (TYK2), exclusively discovered by the company with global patent protection. It achieves selective inhibition of TYK2 by specifically binding to the regulatory pseudokinase JH2 domain of TYK2, and at therapeutic doses, does not inhibit the kinases JAK1, JAK2, and JAK3 of the same family, thereby delivering therapeutic effects while maintaining a favorable safety profile. Inhibition of TYK2 by CS32582 effectively blocks downstream signaling pathways mediated by cytokines such as interleukin (IL)-23, IL-12, and type I interferon (IFN), thereby exerting therapeutic effects on autoimmune diseases including psoriasis.

• The Phase I clinical trial of CS32582 has been completed, and preparations for subsequent Phase I/II development plans are underway.